
Sign up to save your podcasts
Or


Getting back to our usual format, this week we'll discuss the GIACTA trial, which compared various schedules of tocilizumab to various schedules of placebo and prednisone. It's an important trial that has changed the face of GCA and will be a refreshing RCT to discuss before we dive back into garbagey data next week.
By Michael Putman4.9
114114 ratings
Getting back to our usual format, this week we'll discuss the GIACTA trial, which compared various schedules of tocilizumab to various schedules of placebo and prednisone. It's an important trial that has changed the face of GCA and will be a refreshing RCT to discuss before we dive back into garbagey data next week.

498 Listeners

301 Listeners

124 Listeners

3,354 Listeners

1,142 Listeners

120 Listeners

199 Listeners

515 Listeners

70 Listeners

4 Listeners

369 Listeners

182 Listeners

185 Listeners

20 Listeners

6 Listeners